Also found in: Medical.
MUC1Mucine-1 (protein targeted in Cancerous cells)
References in periodicals archive ?
Like humans, the mice develop tumours that over express a protein known as MUC1 on the surface of their cells.
SUMMARY OF MUCIN IMMUNOHISTOCHEMICAL RESULTS Laboratory MUC 1 number immunohistochemistry MUC1 core C1 [check] -ve -ve C2 [check] -ve -ve C3 [check] -ve -ve C4?
Gendler says MUC1 is found on more than 70 percent of all cancers that kill.
CV301 targets two tumor-associated antigens, CEA and MUC1, which are over-expressed in multiple solid tumours, including lung, bladder and colorectal cancer.
The most common immunophenotype of BilIN is negativity for both MUC1 and MUC2, although an increased expression of MUC1 along with the progression of histologic grade of BilIN has been observed.
2] Nonstandard abbreviations: CTC, circulating tumor cell; EpCAM, epithelial cell adhesion molecule; CK, cytokeratins; DAPI, 4',6-diamidino-2-phenylindole; HER2, human epidermal growth factor receptor 2; FACS, fluorescence-activated cell sorting; ERCC1, excision repair cross-complementation group 1; MUC1, mucin 1, cell surface associated; CA, cancer antigen.
En el hombre, los genes que codifican para las mucinas estan programados para configurar 19 familias divididas en dos grupos: el primero son las mucinas ancladas a la membrana, siendo las mas importantes las mucinas MUC1, MUC3, MUC4; el segundo grupo son las mucinas secretadas, siendo las principales las mucinas MUC2, MUC5AC, MUC5B y MUC6.
MUC1 (EMA) is preferentially expressed by ALK positive anaplasitc large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.
Estrogenic effects of nenylphenol on pS2, ER and MUC1 gene expression in human breast cancer cells-MCF-7.
BrevaRex MAb targets the tumor associated antigen MUC1 and has successfully completed a Phase I safety and immunology study.
Contributing to this fact is heavily utilized drug target strategies like: GNRHR and MUC1.
The Phase 2 clinical trial will explore the potential of combining Transgene's TG4010, an investigational therapeutic vaccine designed to generate an immune response against MUC1 expressing tumors such as NSCLC, in conjunction with Bristol-Myers Squibb's immune checkpoint inhibitor, Opdivo, designed to alleviate immune suppression.